U.S. Venture Partners

U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the past thirty-plus years of the firm's existence. Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.

Dale Holladay

CPA / CFO

Rick Lewis

General Partner

Dafina Toncheva

General Partner

556 past transactions

Surgical Safety Technologies delivers data-driven AI technology to hospitals for safe surgeries. It empowers surgeons with an objective assessment of technical and non-technical proficiency using academically validated frameworks.

TaskHuman

Series B in 2022
TaskHuman is a real-time digital coaching platform that offers 1-on-1 interactive sessions with live wellness coaches through video calls. With this platform, users can discover and connect with the world’s most comprehensive global network of coaches, instructors, and specialists covering over 1,000 aspects of one's well-being, such as physical fitness, mental well-being, spiritual, emotional, financial, career & leadership coaching, and more.

Nfinite

Series B in 2022
Nfinite develops a cutting-edge CGI platform that leverages AI and 3D technology to help brands and retailers enhance their sales with limitless product visual experiences. Our new offering includes comprehensive AI training and fine-tuning services, utilizing high-quality synthetic data to tailor AI models for specific industry needs. This ensures superior performance, reduced deployment times, and improved rendering efficiency, making us the ideal partner for AI-driven initiatives across various industries. The company was founded in 2017 and is based in the US and in France.

Carlsmed

Series B in 2022
Provider of medical technology for spine surgery. The company’s proprietary aprevo™ digital-to-device 3-D printed implant system for spine is first-ever surgical implant to be designated by the FDA as a breakthrough technology. Hospital and surgeon customers across the country choose aprevo™ for the benefits of personalized medicine in lumbar fusion surgery. Carlsmed was founded in 2018 and is headquartered in San Diego, California.

IONIX

Series A in 2022
IONIX is the attack surface management solution that uses Connective Intelligence to shine a spotlight on exploitable risks across your real attack surface and its digital supply chain. Only IONIX discovers and monitors every internet-facing asset and connection, delivers laser focus into the most important risks to your business, and provides the tools to rapidly remediate exploitable threats and reduce attack surface risk. Global leaders including Infosys, Warner Music Group, The Telegraph, and E. ON depend on IONIX’s machine learning-powered discovery engine, contextual risk assessment and prioritization, and end-to-end remediation workflow to go on the offensive in managing their complex and ever-changing attack surfaces.

Kryptowire

Venture Round in 2022
Kryptowire was jumpstarted by the Defense Advanced Research Projects Agency (DARPA) and the Department of Homeland Security (DHS S&T), and has been vetted by the US military, law enforcement, and intelligence agencies. Kryptowire provides mobile application security analysis tools, anti‐piracy technologies, mobile app marketplace security analytics, and Enterprise Mobility Management (EMM) solutions. Kryptowire was founded in 2011, is based in Fairfax, Virginia, and has a customer base ranging from government agencies to national cable TV companies.

Nfinite

Series A in 2022
Nfinite develops a cutting-edge CGI platform that leverages AI and 3D technology to help brands and retailers enhance their sales with limitless product visual experiences. Our new offering includes comprehensive AI training and fine-tuning services, utilizing high-quality synthetic data to tailor AI models for specific industry needs. This ensures superior performance, reduced deployment times, and improved rendering efficiency, making us the ideal partner for AI-driven initiatives across various industries. The company was founded in 2017 and is based in the US and in France.

Hunters

Series C in 2022
Hunters SOC Platform empowers security teams to automatically identify and respond to incidents that matter, helping teams mitigate real threats faster and more reliably than SIEM.

Qnovo

Series C in 2022
Qnovo is redefining the foundation of mobility and technology for a more resilient and mobile future—the lithium-ion battery. Since 2010, Qnovo has enabled the electrification revolution with its intelligent battery management software and predictive analytics that improves the performance of electric vehicles, energy storage systems, and consumer devices with enhanced health and safety. Qnovo is working with the world’s top automotive OEMs, holds over 50 patents in the space, and the first generation of Qnovo technology is on more than 150 million smartphones worldwide. The company is headquartered in Milpitas, California. Its investors include BorgWarner, OGCI Climate Investments, Constellation Technology Ventures, BlueRun Ventures, U.S. Venture Partners and RockPort Capital. Visit www.qnovo.com.

Route 92 Medical

Series E in 2021
Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California.

TaskHuman

Series A in 2021
TaskHuman is a real-time digital coaching platform that offers 1-on-1 interactive sessions with live wellness coaches through video calls. With this platform, users can discover and connect with the world’s most comprehensive global network of coaches, instructors, and specialists covering over 1,000 aspects of one's well-being, such as physical fitness, mental well-being, spiritual, emotional, financial, career & leadership coaching, and more.
eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select messenger RNA into proteins that are frequent culprits in key disease driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK 1/2 inhibitor. KICKSTART, a randomized, double-blind, placebo controlled Phase 2b trial of tomivorsertib in NSCLC in combination with pembrolizumab is currently open for enrollment. Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently in the dose-escalation portion of a Phase 1/2 trial, with Phase 2a expansion cohorts expected to initiate in the second half of 2021. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

Hunters

Series B in 2021
Hunters SOC Platform empowers security teams to automatically identify and respond to incidents that matter, helping teams mitigate real threats faster and more reliably than SIEM.

Carrot Fertility

Series C in 2021
Carrot Fertility is a fertility treatment center that provides financial and medical services for employees. Their program includes egg freezing, in vitro fertilization, donor, gestational carrier services, adoption, and pregnancy. They help people through fertility preservation, male-factor infertility, postpartum, gestational surrogacy, and menopause.

Human Interest

Series D in 2021
Human Interest is a 401(k) provider that makes it easy for small and medium-sized businesses to help their employees save for retirement. The company built an end-to-end technology to solve administrative and compliance problems for small and medium-sized businesses. It also offers easy and affordable employee retirement plans and helped thousands of businesses across America to offer retirement accounts to their employees. In 2015, the San Francisco, California-headquartered company was formed by Paul Sawaya and Roger Lee.

Ribon Therapeutics

Series C in 2021
Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms. The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveries in the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners.

Standard Bariatrics

Series B in 2021
Standard Bariatrics is a medical device company that develops and offers surgical instruments for weight-loss surgeries. The company offers Standard Clamp, an instrument that helps surgeons standardize their individual techniques to reduce variation, improve efficiency, and eliminate waste when performing a laparoscopic sleeve gastrectomy. Standard Bariatrics was founded in 2014 and is based in Cincinnati, Ohio.

Oliver Space

Series A in 2021
Oliver Space is a home furnishing company that makes living spaces easy and affordable. The company offers a flexible payment structure that customers can try before they buy at 0% interest. Oliver Space was established in 2018 in San Francisco, California by Chan Park.

Sparrow Pharmaceuticals

Series A in 2021
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess. It was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, a novel treatment designed to target the source of active intracellular corticosteroids in key tissues. The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.

Informed

Series A in 2021
Informed helps banks accelerate their digital transformation with turn-key robotic process automation capable of performing real-time income verification, identity verification, residence verification, and insurance verification tasks. Banks use Informed to reduce their manual costs associated with reviewing documents, catch fraud, reduce bias, and cut down on errors when originating loans and opening accounts.

AirEye

Series A in 2021
AirEye Dome is the only solution that provides full protection against any form of airborne attacks launched against the organizational network. Digital airborne attacks leverage wireless communications (incl. Wifi, cellular, 5G, and Bluetooth) in the corporate airspace in order to gain unauthorized network access, hijack the network or leak data. These are also common entry points in an APT attack. The platform monitors all wireless communications in real-time. Any violation of corporate security is detected and attacks are automatically blocked. Findings are sent to the company SIEM, eliminating the need for platform management and alert chasing. AirEye Dome is a SaaS platform that seamlessly complements your existing network security infrastructure, without the need for architectural changes or messy integrations. The platform is deployed at various industries, including finance, banking, telco, healthcare, manufacturing, retail and aerospace.

Territory Foods

Series B in 2021
Territory Foods is a chef-prepared meal delivery service that creates nutritionist-approved menus tailored to support various dietary preferences and regional market tastes. Its fresh, healthy, ready-to-eat meals are designed by in-house culinary professionals and nutrition experts, prepared by a dedicated team of chefs, and powered by a proprietary algorithm that informs personalized menu variety at scale. Its boredom-proof rotating menus feature a wide variety of freshly-made artisan meals per week that are responsibly sourced, always free of refined sugars, and made without ingredients that contain gluten and dairy. Menus can be customized to meet dietary templates such as Vegan, Vegetarian, Whole30, and Keto, taking the guesswork out of navigating and committing to healthy eating. Territory Foods launched in 2011 and is headquartered in Arlington, VA.

Dapper Labs

Venture Round in 2021
Dapper Labs, the company behind NBA Top Shot, uses blockchain technology to bring NFTs and new forms of digital engagement to fans around the world. Since it was founded in 2018, Dapper Labs has given consumer enthusiasts a real stake in the game by bringing them closer to the brands they love, building engaged and exciting communities for them to contribute to, and producing new pathways for them to become creators themselves.

Act-On Software

Venture Round in 2021
Act-On Software is a developer of a cloud-based integrated marketing platform for midsized businesses. It provides an integrated workspace to address the needs of the customer experience, from brand awareness and demand generation to retention and loyalty. With Act-On, marketers can drive better business outcomes and see higher customer lifetime value.

Neuros Medical

Series B in 2021
Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.

Carlsmed

Series A in 2020
Provider of medical technology for spine surgery. The company’s proprietary aprevo™ digital-to-device 3-D printed implant system for spine is first-ever surgical implant to be designated by the FDA as a breakthrough technology. Hospital and surgeon customers across the country choose aprevo™ for the benefits of personalized medicine in lumbar fusion surgery. Carlsmed was founded in 2018 and is headquartered in San Diego, California.

Edgewise Therapeutics

Series C in 2020
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

Percepto

Series B in 2020
Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Shoulder Innovations

Venture Round in 2020
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.

Stensul

Series B in 2020
Stensul is transforming the way enterprise marketers work. Our email generation platform is centralized, scalable, and pre-configured to each brand. By bypassing all of the back-and-forth with designers, developers and QA, marketers can focus on crafting content that inspires and delivers real results. Build emails in our platform, and then instantly send them out through your ESP or Marketing Cloud. With stensul, marketers are reimagining what’s possible with email.

Silverback Therapeutics

Series C in 2020
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

Medigate by Claroty

Series B in 2020
Securing the clinical environment requires a coordinated approach as IT, IoMT, IoT, and BAS, also known as Cyber-Physical Systems (CPS) converge, and the threat of bad actors exploiting vulnerabilities across new and old infrastructure increases. A comprehensive CPS cybersecurity program requires detailed knowledge of every device, proprietary protocols, and an understanding of medical workflows. With a network with hundreds of different device types, thousands of devices from different manufacturers, and a mix of protocols and operational parameters, it can be overwhelming. Claroty has redefined cyber-physical systems (CPS) protection with an unrivaled industry-centric platform built to secure mission-critical infrastructure. The Claroty Platform provides the deepest asset visibility and the broadest, built-for-CPS solution in the market comprising exposure management, network protection, secure access, threat detection, and operational efficiency. Backed by award-winning threat research and a breadth of technology alliances, The Claroty Platform enables organizations to effectively reduce CPS risk, with the fastest time-to-value and lower total cost of ownership. Claroty is deployed by hundreds of organizations at thousands of sites globally. The company is headquartered in New York City and has a presence in Europe, Asia-Pacific, and Latin America. To learn more, visit claroty.com.

Optimize Health

Series A in 2020
Optimize Health is a provider of a digital healthcare platform that enables the deployment of Remote Patient Monitoring (RPM) programs. It uses easy-to-use equipment and software. The software is designed to facilitate provider compliance when billing to new Medicare CPT codes for RPM while providing a great user experience for both patients and providers. Its system is designed to be profitable for physicians starting in the first month.

Carrot Fertility

Series B in 2020
Carrot Fertility is a fertility treatment center that provides financial and medical services for employees. Their program includes egg freezing, in vitro fertilization, donor, gestational carrier services, adoption, and pregnancy. They help people through fertility preservation, male-factor infertility, postpartum, gestational surrogacy, and menopause.

Hunters

Series A in 2020
Hunters SOC Platform empowers security teams to automatically identify and respond to incidents that matter, helping teams mitigate real threats faster and more reliably than SIEM.

Okami Medical

Series D in 2020
Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliable regardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason. It was founded in 2011 and is headquartered in Aliso Viejo, California.

Zerto

Series F in 2020
Zerto provides business continuity software solutions to keep enterprise and cloud IT running 24/7. Through the Zerto Cloud Continuity Platform, organizations can protect and move virtualized workloads between public, private, and hybrid clouds. Its flagship product, Zerto Virtual Replication, allows users to protect, recover and migrate applications in the cloud and virtualized data centers. It was founded in 2009 and headquartered in Boston, Massachusetts.

Cato Networks

Series D in 2020
Cato Networks provides organizations with a cloud-based and secure global SD-WAN. Cato delivers an integrated networking and security platform that securely connects all enterprise locations, people, and data. Cato Cloud cuts MPLS costs, improves performance between global locations and cloud applications, eliminates branch appliances, provides secure Internet access everywhere, and seamlessly integrates mobile users, and cloud data centers into the WAN.

Forager

Series A in 2020
Forager is a venture-backed innovator in the cross-border logistics industry. With a combination of cutting-edge technology and decades of industry experience, the company tackles the problems cross-border shippers are facing with technology-focused solutions and years of logistics experience. It also delivers seamless and modern transportation solutions for its customers. The company also features an easy-to-use web-based transportation management platform to bring a higher level of service to the industry. Forager was founded in 2018 and is headquartered in Chicago, Illinois.

Arkose Labs

Series B in 2020
The mission of Arkose Labs is to create an online environment where all consumers are protected from online spam and abuse. Recognized by G2 as the 2023 Leader in Bot Detection and Mitigation, with the highest score in customer satisfaction and largest market presence four quarters running, Arkose Labs offers the world's first $1M warranties for credential stuffing and SMS toll fraud. With 20% of our customers being Fortune 500 companies, our AI-powered platform combines powerful risk assessments with dynamic threat response to undermine the strategy of attack, all while improving good user throughput. Headquartered in San Mateo, CA, with offices in London, Costa Rica, and Brisbane, Australia, Arkose Labs protects enterprises from cybercrime and abuse.

Silverback Therapeutics

Series B in 2020
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

HealthJoy

Series C in 2020
HealthJoy is a benefits experience platform helping companies save money while improving employee satisfaction. Through personalized guidance and AI technology, it empowers employees to better use and understand their benefits. The result is happier employees, increased cost containment, and fewer questions for HR. HealthJoy integrates a client’s existing benefits to deliver each employee a personalized digital benefits wallet that keeps benefits top-of-mind. Employees also gain on-demand access to online medical consultations, live healthcare concierges, Rx savings, and much more. HealthJoy empowers employees to become educated healthcare shoppers and fundamentally changes healthcare dynamics.

Epsagon

Series A in 2020
Epsagon’s SaaS platform allows Dev and Ops teams to troubleshoot less and fix issues faster by providing automated data correlation, payloads, and end-to-end observability within microservice environments. With our lightweight agent SDK, Epsagon provides automated instrumentation and tracing without gaps in coverage, giving you full visibility for containers, VMs, serverless, and more with no training, manual coding, tagging or maintenance required. Epsagon helps organizations and teams of all sizes to optimize costs through unlimited free monitoring and scalable pricing and increase engineering efficiency through reduced application downtime, faster shipping of features, and time saved in identifying and correcting issues.

ShiraTronics

Series A in 2019
ShiraTronics develops neuromodulation technology to combat debilitating chronic migraine. The company is driven by a mission to transform the lives of those living with chronic migraine.

Kenna Security

Series D in 2019
Kenna is a SaaS risk and vulnerability intelligence platform that accurately measures risk and prioritizes remediation efforts. The Kenna Security Platform enables organizations to work cross-functionally to determine and remediate cyber risks. Kenna leverages Cyber Risk Context Technology™ to track and predict real-world exploitations, focusing security teams on what matters most. Headquartered in San Francisco, Kenna counts among its customers many Fortune 100 companies and serves nearly every major vertical.

Primary

Series C in 2019
Primary makes clothes for kids and builds a better experience for busy parents to shop for them. It aims to be the most inclusive kid's clothing brand, offering high-quality essentials at affordable prices. Rather than chasing the trend, Primary offers thoughtfully designed clothing without logos, slogans, or sequins. They take a gender-neutral approach, with a broad range of colors available for babies and kids 0-12, without prescribing what is for girls or boys. It was founded in 2015 and is headquartered in New York, New York.

Edgewise Therapeutics

Series B in 2019
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

Luma Health

Series B in 2019
Luma Health patients should be able to connect to their healthcare provider in a way that’s modern and mobile-first. Their services include healthcare, patients, appointments, scheduling, patient messaging, patient engagement, patient communication, public health, patient access, and more.

Entelo

Venture Round in 2019
Entelo applies intelligence to big data to help modern recruiters find, qualify, and acquire talent. Today over 600 customers of all sizes and industries trust Entelo to provide their talent acquisition teams with higher candidate engagement, actionable insights, and increased productivity. To learn how leading companies such as Capital One, Cisco, Facebook, GE, Genentech, Netflix, Northrop Grumman, and Target are building their organizations using Entelo, visit www.entelo.com.

Rimeto

Series A in 2019
Rimeto, a four-year-old startup that provides customers with more detailed employee directories and profiles. Our mission is to help people collaborate at work - to empower people with access to information, enable them to build great things together, and help them feel truly connected to their colleagues. Rimeto builds people-centric tools for the modern workplace - beautiful, powerful and flexible. We believe that work is better when information is easily accessible, searchable and actionable. Everyone should be able to see across their organization and tap into collective knowledge. Starting with an advanced directory, we're creating a platform around the enterprise graph.

Human Interest

Series B in 2019
Human Interest is a 401(k) provider that makes it easy for small and medium-sized businesses to help their employees save for retirement. The company built an end-to-end technology to solve administrative and compliance problems for small and medium-sized businesses. It also offers easy and affordable employee retirement plans and helped thousands of businesses across America to offer retirement accounts to their employees. In 2015, the San Francisco, California-headquartered company was formed by Paul Sawaya and Roger Lee.

Cleave Therapeutics

Series C in 2019
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

Omada

Series D in 2019
Omada Health is a digital care company that offers innovative and clinically effective digital health programs to empower individuals to engage in their health and lead healthier lives. The program is personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, type 2 diabetes management, hypertension, behavioral health, and musculoskeletal issues. Omada combines professional health coaching, connected health devices, real-time data, and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program.

Dstillery

Series D in 2019
Dstillery, Inc. is a digital intelligence platform that specializes in custom audience solutions for brands and their media partners. Founded in 2008 and based in New York, the company offers a range of marketing solutions designed to enhance brand awareness, consideration, and customer retention. Dstillery's premier product, Custom AI Audiences, utilizes tailored artificial intelligence models to deliver accurate and scalable audience targeting. The platform integrates mobile location insights with desktop behaviors, optimizing marketing efforts across various channels, including mobile, desktop, and video. Dstillery also provides geospatial insights through its Dscover Maps tool, allowing brands to analyze market composition by geography. The company serves a diverse clientele across multiple sectors, including retail, finance, and technology, helping them leverage customer data to drive revenue growth and improve audience engagement.

Percepto

Series A in 2019
Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Happy Returns

Venture Round in 2019
Happy Returns provides comprehensive return solutions for the world's leading online and omnichannel retailers and their customers. They provide aggregated shipping and logistics across all channels with optimized delivery to retailers' preferred destinations.

HealthJoy

Series B in 2019
HealthJoy is a benefits experience platform helping companies save money while improving employee satisfaction. Through personalized guidance and AI technology, it empowers employees to better use and understand their benefits. The result is happier employees, increased cost containment, and fewer questions for HR. HealthJoy integrates a client’s existing benefits to deliver each employee a personalized digital benefits wallet that keeps benefits top-of-mind. Employees also gain on-demand access to online medical consultations, live healthcare concierges, Rx savings, and much more. HealthJoy empowers employees to become educated healthcare shoppers and fundamentally changes healthcare dynamics.

Nuvaira

Series E in 2019
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Medigate by Claroty

Series A in 2019
Securing the clinical environment requires a coordinated approach as IT, IoMT, IoT, and BAS, also known as Cyber-Physical Systems (CPS) converge, and the threat of bad actors exploiting vulnerabilities across new and old infrastructure increases. A comprehensive CPS cybersecurity program requires detailed knowledge of every device, proprietary protocols, and an understanding of medical workflows. With a network with hundreds of different device types, thousands of devices from different manufacturers, and a mix of protocols and operational parameters, it can be overwhelming. Claroty has redefined cyber-physical systems (CPS) protection with an unrivaled industry-centric platform built to secure mission-critical infrastructure. The Claroty Platform provides the deepest asset visibility and the broadest, built-for-CPS solution in the market comprising exposure management, network protection, secure access, threat detection, and operational efficiency. Backed by award-winning threat research and a breadth of technology alliances, The Claroty Platform enables organizations to effectively reduce CPS risk, with the fastest time-to-value and lower total cost of ownership. Claroty is deployed by hundreds of organizations at thousands of sites globally. The company is headquartered in New York City and has a presence in Europe, Asia-Pacific, and Latin America. To learn more, visit claroty.com.

Cato Networks

Series C in 2019
Cato Networks provides organizations with a cloud-based and secure global SD-WAN. Cato delivers an integrated networking and security platform that securely connects all enterprise locations, people, and data. Cato Cloud cuts MPLS costs, improves performance between global locations and cloud applications, eliminates branch appliances, provides secure Internet access everywhere, and seamlessly integrates mobile users, and cloud data centers into the WAN.

HighLife

Series B in 2019
HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation. The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology.

Ribon Therapeutics

Series B in 2019
Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms. The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveries in the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners.

NeoChord

Series D in 2018
NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3-inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation. In contrast, most mitral valve repair procedures are performed through a 3 to 10-inch chest incision (sternotomy) which involves cutting through the sternum, opening the rib cage, stopping the heart and placing the patient on bypass. Founded in 2007 and is based in St. Louis Park, MN.

ZypMedia

Series C in 2018
Zypmedia provides local ad sales executives and their customers an opportunity to grow their business and evolve with a changing media environment. ZypMedia is a full-stack digital advertising technology platform that combines the power of machine learning with the intelligence of human experts to specialize in local-focused advertising. The company's innovative, intelligent tools enable you to bridge the audience gap between traditional and digital worlds, expand your offerings to better reach your local audience, and significantly grow your revenue.

Arkose Labs

Series A in 2018
The mission of Arkose Labs is to create an online environment where all consumers are protected from online spam and abuse. Recognized by G2 as the 2023 Leader in Bot Detection and Mitigation, with the highest score in customer satisfaction and largest market presence four quarters running, Arkose Labs offers the world's first $1M warranties for credential stuffing and SMS toll fraud. With 20% of our customers being Fortune 500 companies, our AI-powered platform combines powerful risk assessments with dynamic threat response to undermine the strategy of attack, all while improving good user throughput. Headquartered in San Mateo, CA, with offices in London, Costa Rica, and Brisbane, Australia, Arkose Labs protects enterprises from cybercrime and abuse.

Raken, Inc.

Series A in 2018
Raken provides mobile-first technology to streamline field workflows for the construction industry. Raken's digital toolbox connects the field to the office with daily reports, time cards, toolbox talks, photo management, production tracking and more. Swinerton Renewable Energy, John W. Danforth, Broadway Mechanical and thousands of other top general contractor and subcontractor firms use Raken for their field reporting needs. To find out more, visit www.rakenapp.com.

Luma Health

Series A in 2018
Luma Health patients should be able to connect to their healthcare provider in a way that’s modern and mobile-first. Their services include healthcare, patients, appointments, scheduling, patient messaging, patient engagement, patient communication, public health, patient access, and more.

Inari Medical

Series C in 2018
Inari Medical is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. They are focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. It has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.

Kenna Security

Series C in 2018
Kenna is a SaaS risk and vulnerability intelligence platform that accurately measures risk and prioritizes remediation efforts. The Kenna Security Platform enables organizations to work cross-functionally to determine and remediate cyber risks. Kenna leverages Cyber Risk Context Technology™ to track and predict real-world exploitations, focusing security teams on what matters most. Headquartered in San Francisco, Kenna counts among its customers many Fortune 100 companies and serves nearly every major vertical.

Luminate Security

Series A in 2018
Luminate enables IT teams to create Zero Trust Application Access architecture through connecting any user from any device to any corporate application while seamlessly reducing attack surface, increasing visibility into application usage and improving corporate compliance. They secure access to any corporate resource or application, hosted on any datacenter, whether on the cloud or on-premises. They leverage the Software-Defined Perimeter principles: resources are always cloaked from public discovery, access to specific participants is restricted via trust broker, users are authenticated and authorized prior to accessing any application. Luminate Secure Access Cloud is agentless, it is deployed in less than 5 minutes and, once in place, it provides both full visibility of users’ actions when accessing corporate resources, as well as complete governance and risk mitigation of these resources.

Intuity Medical

Debt Financing in 2018
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Happy Returns

Series B in 2017
Happy Returns provides comprehensive return solutions for the world's leading online and omnichannel retailers and their customers. They provide aggregated shipping and logistics across all channels with optimized delivery to retailers' preferred destinations.

Imperva

Series B in 2017
Imperva provides activity monitoring, real-time protection, and risk management solutions for critical business data and applications. Imperva is a leading provider of cybersecurity solutions that protect business-critical data and applications in the cloud and on-premises It was founded by Shlomo Kramer, Amichai Shulman and Mickey Boodaei in 2002 and is based in Redwood Shores, California.

Neuros Medical

Series A in 2017
Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.

Effector Therapeutics

Series C in 2017
eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select messenger RNA into proteins that are frequent culprits in key disease driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK 1/2 inhibitor. KICKSTART, a randomized, double-blind, placebo controlled Phase 2b trial of tomivorsertib in NSCLC in combination with pembrolizumab is currently open for enrollment. Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently in the dose-escalation portion of a Phase 1/2 trial, with Phase 2a expansion cohorts expected to initiate in the second half of 2021. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

Primary

Series B in 2017
Primary makes clothes for kids and builds a better experience for busy parents to shop for them. It aims to be the most inclusive kid's clothing brand, offering high-quality essentials at affordable prices. Rather than chasing the trend, Primary offers thoughtfully designed clothing without logos, slogans, or sequins. They take a gender-neutral approach, with a broad range of colors available for babies and kids 0-12, without prescribing what is for girls or boys. It was founded in 2015 and is headquartered in New York, New York.

Entelo

Series C in 2017
Entelo applies intelligence to big data to help modern recruiters find, qualify, and acquire talent. Today over 600 customers of all sizes and industries trust Entelo to provide their talent acquisition teams with higher candidate engagement, actionable insights, and increased productivity. To learn how leading companies such as Capital One, Cisco, Facebook, GE, Genentech, Netflix, Northrop Grumman, and Target are building their organizations using Entelo, visit www.entelo.com.

Omada

Series C in 2017
Omada Health is a digital care company that offers innovative and clinically effective digital health programs to empower individuals to engage in their health and lead healthier lives. The program is personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, type 2 diabetes management, hypertension, behavioral health, and musculoskeletal issues. Omada combines professional health coaching, connected health devices, real-time data, and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program.

HelloSign

Series B in 2017
We believe that the way business gets done today is broken. That’s why we’re dedicated to simplifying work for everyone - from small startups to large enterprise companies. Millions of individuals and over 60,000 companies world-wide trust the HelloSign platform – which includes eSignature, digital workflow and eFax solutions – to automate and manage their most important business transactions. With a sharp focus on user experience and a lust for innovation, HelloSign is on a mission to Simplify Work.

Route 92 Medical

Venture Round in 2017
Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California.

Chute

Series B in 2017
Chute empowers marketers to turn visual content into engagement and actionable insights, curate the best photos and videos from fans, obtain permission to use their content, gain valuable insights about influencers. It was founded in 2011 and headquartered in San Francisco, California.

HotelTonight

Series E in 2017
HotelTonight is a hotel booking application that is made for mobile from the ground up. HotelTonight offers some of the best pricing for last-minute hotel deals booked up to 7 days in advance. Perfect for business travelers, leisure travelers, and locals alike. HotelTonight was founded in 2010 and headquartered in San Francisco, California.

InsideSales

Series D in 2017
InsideSales provides a SaaS sales engagement solution by a data intelligence engine that accelerates revenue by improving the productivity of sales teams. Their cloud offering integrates with CRM platforms and automatically captures shareable data insights buyer interactions on the platform and delivers them directly to their workflows. They follow strategic contact strategies with these embedded insight accounts, contacts, and sales activities, and optimize engagement across the funnel.

Kenna Security

Series B in 2016
Kenna is a SaaS risk and vulnerability intelligence platform that accurately measures risk and prioritizes remediation efforts. The Kenna Security Platform enables organizations to work cross-functionally to determine and remediate cyber risks. Kenna leverages Cyber Risk Context Technology™ to track and predict real-world exploitations, focusing security teams on what matters most. Headquartered in San Francisco, Kenna counts among its customers many Fortune 100 companies and serves nearly every major vertical.

Inspire Medical Systems

Series F in 2016
Inspire Medical Systems is a developer of innovative, implantable neurostimulation technologies to treat Obstructive Sleep Apnea (OSA). Utilizing well-established technologies from the fields of cardiac pacing and neurostimulation, Inspire has developed a proprietary Upper Airway Stimulation (UAS) therapy for patients who suffer from OSA.

Intuity Medical

Venture Round in 2016
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Pluto TV

Series B in 2016
Pluto TV is a free streaming television service in America, offering over 100 live and original channels along with thousands of on-demand movies. The service collaborates with major TV networks, movie studios, publishers, and digital media companies. It is used by millions of viewers each month for news, TV shows, movies, sports, lifestyle content, and digital series. Pluto TV, headquartered in Los Angeles, is accessible on mobile devices, web browsers, and connected TV streaming devices.

SentreHEART

Series D in 2016
SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada.

Cato Networks

Series B in 2016
Cato Networks provides organizations with a cloud-based and secure global SD-WAN. Cato delivers an integrated networking and security platform that securely connects all enterprise locations, people, and data. Cato Cloud cuts MPLS costs, improves performance between global locations and cloud applications, eliminates branch appliances, provides secure Internet access everywhere, and seamlessly integrates mobile users, and cloud data centers into the WAN.

Electric Cloud

Series F in 2016
Electric Cloud is the leader in DevOps Release Automation. They help organizations developing enterprise web/IT, mobile and embedded systems applications deliver better software faster by automating and accelerating build, deployment and release processes at scale. Leading organizations like Cisco, E*TRADE, Gap, GE, HP, Intel, Lockheed Martin, Sony, and Qualcomm use Electric Cloud solutions and services to boost DevOps productivity and Agile throughput while providing a scalable, auditable, predictable and high-performance pathway to production.

Cleave Therapeutics

Series B in 2016
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

Apptimize

Series B in 2016
Apptimize lets mobile teams increase revenue and engagement by iterating faster and smarter. Our mission is to enable you to optimize, deploy, and manage the features and UX of your native iOS and Android apps in real-time through instant updates, A/B testing, feature flags, and analytics. We work with top apps like the Wall Street Journal, Western Union, Flipagram, HotelTonight, Nokia, and Trulia.

Appthority

Series B in 2016
Appthority is a pioneer in enterprise mobile security and the leader in the Mobile Threat Defense category. The comprehensive Appthority Mobile Threat Protection (MTP) solution helps customers keep their data private and secure from mobile device, app and network threats. More Fortune 1000 companies trust Appthority to secure their enterprises from mobile threats because Appthority delivers best-in-class mobile threat protection and unparalleled enterprise visibility and control of mobile risks. With Appthority, security teams are informed, employees are productive and enterprise data is kept private and secure. Learn more at www.appthority.com.

Primary

Series A in 2016
Primary makes clothes for kids and builds a better experience for busy parents to shop for them. It aims to be the most inclusive kid's clothing brand, offering high-quality essentials at affordable prices. Rather than chasing the trend, Primary offers thoughtfully designed clothing without logos, slogans, or sequins. They take a gender-neutral approach, with a broad range of colors available for babies and kids 0-12, without prescribing what is for girls or boys. It was founded in 2015 and is headquartered in New York, New York.

ZEFR

Series E in 2016
Zefr is a video advertising company that creates targeted video ad placements with it's unique and proprietary technology. With our custom packages, we leverage both technology and human review to selected individual videos, ensuring brands can safely and effectively scale their video ad campaigns. Why the name Zefr? Before Venice became “Silicon Beach” it was the grimy paradise of the 1970's Zephyr skate team. The Z-boys were a group of broken-home-punks that pioneered today’s skate culture. They did more than just push the physical boundaries of the sport—they created the culture that defines Venice today. At Zefr, we embrace the Z-boy’s drive for innovation, performance, and pushing boundaries. Our motto? Go Big. Go Fast.

Ribon Therapeutics

Series A in 2016
Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms. The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveries in the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners.

PlaceIQ

Series D in 2016
PlaceIQ is a data and technology provider that powers critical business and marketing decisions with location data, analytics, and insights. An early industry pioneer, PlaceIQ has become the standard for fueling better outcomes for marketers, analysts, and publishers through powerful, location-based consumer insights, real-world measurement, and attribution. With PlaceIQ, companies can uncover opportunities within the consumer journey by learning about and connecting with location-based audiences, measuring real-world ROI, and applying insights that drive intelligent marketing and successful business outcomes.

Zerto

Series E in 2016
Zerto provides business continuity software solutions to keep enterprise and cloud IT running 24/7. Through the Zerto Cloud Continuity Platform, organizations can protect and move virtualized workloads between public, private, and hybrid clouds. Its flagship product, Zerto Virtual Replication, allows users to protect, recover and migrate applications in the cloud and virtualized data centers. It was founded in 2009 and headquartered in Boston, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.